What stands out as a possible new cancer target to therapeutically drug?
Every year as part of our AACR Preview series, I pick a novel target to illustrate where innovative ideas are coming to the fore based on new and often early scientific evidence.
There is also the hope they might lead to future clinical drug development and emerging pipelines.
Some of these targets can turn out to be tough to drug for various reasons, including narrow therapeutic windows limiting the dosing schedule that can be realistically achieved (bromodomains come to mind), while others lead to some intriguing compounds which end up going further than expected.
Here’s the sixth article in this year’s series where we identify and discuss an early novel target of interest…
To learn more about the AACR21 data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
At the 2018 AACR annual meeting, one of the noteworthy talks given to the 22,000+ attendees in Chicago was a plenary lecture by Charles Swanton from the Francis Crick Institute in London. He’s a Professor of Personalized Cancer Medicine at University College London and chief clinician for Cancer Research UK (CRUK).
Professor Swanton is the leader of a landmark clinical study, TRACERx (TRAcking Cancer Evolution through therapy (Rx)) study, which involves analyzing how cancers and in particular, lung and renal cancers, evolve over time.
There’s a lot of heavy science and jargon inherent in this niche that often frightens off people, but that need not always be the case.
What is fascinating, though, is the very idea that tracking the development of early stage cancers might teach us new insights and lessons about alternative approaches to oncology R&D.
We have all seen the limitations of chemotherapy, targeted therapies and even immune checkpoint blockade, so what other approaches can be considered that link back to the biology of the disease and how it evolves over time?
What we wanted to achieve here was a clear and elegant story about what Prof Swanton and his colleagues are doing, as well as a simple grounding on the basics of disease progression and how that can translate clinically into new therapeutics that might make a real difference to the lives of people with cancer.
It’s a fascinating story and may well be one of the most underappreciated recent developments in cancer research…
To learn more and get a heads up on our latest thought leader interview and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.